Patent Application
20170045532
Field of the Invention
The present invention has to do with the detection of infection following implantation of a prosthetic material or device on and/or into bones and joints. The invention has both human and veterinary applications.
The Related Art
There is a risk of infection following implantation of any prosthetic material or device in a physiologically sterile site or organ such as bone and joints. Any kind of internal or external orthopedic implants, including but not limited to breast implants, prosthetic heart values, neurosurgical implants (such as vascular clips, shunt tubes and vascular stents) are just a few examples of prosthetic materials and devices that can be the subject of this invention. Diagnosis of infection following surgery can be difficult and in many cases the infection cannot be detected at an early stage. Early stage detection is important because it greatly enhances successful surgical outcomes.
Each infectious process is the conclusion of interaction between a virulent pathogen on one side and the host immune system on the other side. The pathogen causes structural damage to the host tissues and in cases with bone and joint infection, the pathogenesis of infection is associated with damage to peri-implant tissues cells as well as disruption of the extracellular matrix in those tissues. On the other hand, a sufficiently competent immune system will elicit an inflammatory reaction in response to the presence of the microbes which can also cause damage to host tissues as a secondary adverse effect. Therefore, during a peri-implant infection, structural molecules or components specific to microbial cells or host tissues (in this invention the host tissues include bone, cartilage, muscle, ligament, tendon, articular capsule, etcetera) are released into the peri-implant environment and a portion of these molecules will be absorbed into the blood circulation and from blood into the urine.
This invention is based on the idea that a combination of at least two biomarkers, (one specific to the pathogenic microbe and the other specific to destruction of peri-implant tissues) that are detectable in the peripheral blood can be used for diagnosis of peri-implant infections. Any fluid or tissue samples drawn from a peri-implant environment (such as joint aspirate, tissue aspirate, tissue biopsy, etcetera) can be tested for the dual biomarker concept. Moreover, a blood or urine test that is highly sensitive for detecting specific structural microbial molecules and peri-implant tissue components can be convenient and accessible sources for diagnosing peri-implant infection of the bone and joints.
Some benefits of the present invention are as follows:
1. Prophenoloxidase (PPO) pathway can detect presence of peptidoglycan (PG, found in the bacterial cell wall) and betaglucan (BG, found in fungi) in the blood, urine, prosthetic membrane (biofilm) and periprosthetic tissue, including articular capsular, periprosthetic fibrotic tissue, fascia, ligaments, tendons, muscles and even subcutaneous tissue depending on the extent of the infection. Moreover, this phenomenon can be used to detect PG or BG in the tissue material formed at the interface of bone-implant, bone-cement and cement-implant.
2. Any biomarker of destruction of peri-implant tissues such as bone, cartilage, synovium, muscle, fat and other periparticular tissues can be measured in the blood, urine and periprosthetic fluid as indicators of ongoing damage to these tissues due to peri-implant infections. These biomarkers are catabolized or non-modified components of the damaged tissue cells or extracellular matrix and are released by the interaction of the pathogens and/or host immune system with the affected host tissue. Such markers can be identified and measured via antibody-based immunoassay methods (such as enzyme-linked immunosorbent assay or ELISA, radioimmunoassay or RIA, or lateral flow immunoassay) or other non-ELISA based methods (such as chromatography-based, mass-spectrometry-based, gel-electrophoresis-based, western blot, microarrays, metabolemic, lipidomic and proteomic methods) and include but are not limited to biomarkers of bone metabolism, degradation or remodeling, Biomarkers related to collagen metabolism, Biomarkers related to aggrecan metabolism, Biomarkers related to other non-collagenous proteins, Osteoblast-osteoclast regulating factors (Regulatory molecules of osteoblasts and osteoclasts and Biomarkers related to other metabolic processes of bone and joint tissues.
3. The “dual-marker” concept is considered as a combination of any form of diagnostic tests devised based on the above concepts. PPO pathway can be applied for several different specimens (such as blood, urine, peri-implant fluid or tissue samples) to measure the levels of PG or BG. The biomarkers of host tissue destruction can be measured in blood, urine and peri-implant fluid. One or any combination of the above mentioned biomarkers can be utilized in combination with PPO pathway-based test as a diagnostic assay according to the “dual-marker” concept.
4. In patients with persistent surgical wound drainage after primary or revision arthroplasty or other procedures (spine, trauma, etc), PPO pathway can be used to monitor the release of PG or BG into blood or urine. Positivity of dual-marker concept (persistently elevated or increasing levels of PG or BG associated with persistently elevated or increasing levels of biomarkers of damage to peri-implant tissues) can demonstrate early peri-implant postoperative infection of bone and joints.
5. In patients with failed symptomatic implants and suspicion of peri-implant infection of bone and joint, any diagnostic test based on the “dual-marker” concept can be used as a screening tool to measure the level of PG, BG and biomarkers of tissue damage. Detection of PG, BG and biomarkers of tissue damage in the serum can be indicative of peri-implant infection of bone and joint due to continuous release of PG, BG and biomarkers of tissue damage from infected peri-implant tissue and material into the blood.
6. The “dual-maker” concept can be used as a point-of-care test during surgical intervention in cases with failed implants, in whom suspicion of infection exists yet it has not been proven by the available microbiological and non-microbiological tests. Elevated levels of PG or BG in the intraoperative specimens (periprosthetic fluid or tissue samples) can confirm the role of infection in implant failure. This can have a critical impact on the surgeon's decision making during the operation regarding surgical plan and definitive postoperative surgical and medical treatment strategy.
7. The “dual-marker” concept can be used to follow the evolution of peri-implant infection and to determine whether surgical and medical treatment of peri-implant infection has been successful or failed.
8. In patients with peri-implant infection of the joints who undergo the first stage of a two-stage exchange arthroplasty (i.e. removal of the implant and placement of an antibiotic spacer), the “dual-marker” concept can be used to follow the evolution of infection and determine the optimal time for the second stage of this procedure (i.e. removal of the antibiotic spacer and implantation of new definitive prosthesis).
9. In patients with peri-implant infection of the joints who undergo second stage of two-stage exchange arthroplasty, the “dual-marker” concept can be utilized to measure PG, BG and biomarkers of peri-implant tissue destruction in blood and urine in a serial manner and as a follow up test to confirm the success of the treatment of NI.
The following lists various biomarkers.
Biomarkers of Bone Metabolism, Degradation or Remodeling
Biomarkers Related to Collagen Metabolism
Biomarkers Related to Aggrecan Metabolism
Biomarkers Related to Other Non-Collagenous Proteins
Osteoblast-Osteoclast Regulating Factors (Regulatory Molecules of Osteoblasts and Osteoclasts
Biomarkers Related to Other Metabolic Processes of Bone and Joint Tissues
The preferred embodiments are best described by the following examples which are provided in support of the invention.
To assess feasibility and sensibility of the assay, in vitro models of infected synovial fluid samples were developed using Staphylococcus aureus (S. aureus) type ATCC 25923 and Escherchia coli (E. coli) type ATCC 25922. Non-infected synovial fluid samples were obtained from patients undergoing primary total hip or knee replacement in whom the procedure was performed to treat advanced joint osteoarthritis without any past history of infection in the joint. Bacteria were cultured in 10 ml of Trypticase Soy Broth (Becton Dickinson) in a shaker incubator (New Brunswick Scientific Inc, Edison, N.J.) overnight at 37° C. The following morning, bacteria were washed using sterile phosphate buffer saline (PBS) solution and centrifugation (14000 rpm for 5 min). Bacteria were added to sterile PBS solution. Serial 100 ul amounts of whirled bacterial solution were added to 900 ul of sterile PBS until turbidity meter (Dave Barry's) read the sample as 0.10-0.11 that was equivalent to 108 colony-forming units per milliliter (CFU/ml). Serial dilution was performed 7 times to achieve solutions containing 107 to 101 CFU/ml of either S. aureus type ATCC 25923 or E. coli type ATCC 25922 in synovial fluid. Petri films (3M) were incubated with 1 ml solution containing 102 to 104 CFU/ml and were incubated overnight at 37° C. and visible colonies were counted next day to confirm CFU counts of the original solution. 50 ul of each solution was added to 50 ul of silkworm larvae plasma (SLP) reagent solution in microplate wells as instructed by the developer (WAKO chemicals USA, Richmond). The microplate was placed in a microplate reader using a colorimetric assay by measuring light transmittance of the solution of the wells. The setting for microplate reader included wavelength 650 nm, room temperature and 180 cycles of reading with 30-second intervals. (
In order to obtain standard control graphs (positive controls), four serial 10-fold dilutions were performed on the solution containing 4 ugr/ml of peptidoglycan (PG) antigen of S. aureus (provided by WAKO chemicals USA Richmond) to obtain dilution of 40 pg/ml of S. aureus PG antigen. Dilutions were performed using water for injection. (
Several tests were conducted as negative control experiments. One series of control experiments consisted of two 50-ul samples from water for injection (used for dilution of synovial fluid, synovial tissue and blood samples). The experiment with negative control samples (water with injection used for dilution) was repeated in each set of experiments with in vitro models or real clinical samples.
In another series of experiments synovial fluid samples from three different patients with non-infected knee joints including one with primary degenerative osteoarthritis, one with rheumatoid arthritis and one with inflamed Baker's cyst were tested with SLP reagent in undiluted state and dilution of 1:50 using water for injection. The water used for dilution was also tested. All negative controls were assayed using SLP reagent in the same microplate wells and using similar microplate reader setting as described earlier (
Following the preliminary experiments with in vitro models and negative controls, several experiments were conducted using samples from preoperative aspiration or intraoperative sampling of synovial fluid from prosthetic knee or hip joints that underwent revision surgery because of already confirmed or suspected prosthetic infection. SLP assay was performed for these clinical synovial fluid samples in several dilutions including 1:1 (undiluted), 1:10, 1:50, 1:100 and 1:200 using water for injection for dilution. In one clinical scenario, a 66-year old male patient (hereby named as patient #1) presented with progressive right knee pain. As past surgical history, patient #1 had undergone primary total knee replacement due to osteoarthritis two years ago. The patient had complications regarding his surgical wound healing that took several weeks to heal. However, he did not have any sign of deep infection. Shortly after recovery from right total knee replacement, he started to notice progressive pain and effusion in his knee. The patient was evaluated in our institution for pain in his prosthetic right knee. Preoperative evaluation including blood markers for infection (erythrocyte sedimentation rate and C-reactive protein) and aspiration of periprosthetic fluid were negative for infection. However, tri-phasic bone scan suggested an infectious process. Revision knee arthroplasty with an impression of presumably aseptic loosening of his components was recommended. The patient underwent revision surgery and following the surgery, the results of culture of intraoperative sample of periprosthetic tissue was reported to be positive for Streptococcus intermedius. Considering history of surgical wound healing complications at the time of primary knee joint arthroplasty, onset of progressive pain shortly after the index surgery and preoperative tri-phasic bone scan being positive, the surgeon decided to treat the patient as a periprosthetic joint infection (PJI) and the patient started oral antibiotic therapy afterwards. The SLP test was performed on intraoperative samples of this patient and was observed to be positive at dilutions of 1:50 and 1:100. Two negative controls were also performed during this assay (
The infected synovial fluid samples were collected from patients with periprosthetic joint infection in different stages of the evolution of the disease and its treatment. Examples were cases with early postoperative periprosthetic joint infection (patient #2, [
Four samples of infected synovial fluid (from patients #1,2,4 and 5) were assessed by SLP test before and after 7-10 days of storage at −20° C. Graphs are presented in
Out of 9 blood samples of patients with periprosthetic joint infection that were tested for different biomarkers, in five samples the levels of osteopontin were found to be higher than the reference normal range of (7.2-40 ng/ml). The values that were detected were 44, 51, 55, 64, 88 and 219 ng/ml. In three samples from the same group the levels of osteoprotegerin were higher than reference range of 2.3-8.4 pM and were detected to be 9.6, 10 and 11 pM. Two other patients had levels very close to the upper normal limit of the reference range with the values being 8.2 and 8.3 pM. The elevated level of biomarkers indicative of bone destruction together with the elevated level of SLP is likely to be specific for periprsthetic joint infection. The combination of the biomarker indicative of bone destruction together with SLP allows us to reduce the incidence of false positive SLP tests that may be seen in patients with infection arising from sources other than the joint.
Modifications and variations of the foregoing will be apparent to those having skill in the art based upon the disclosures provided herein. For example, variations on dilution, use of centrifuges and use of enzymes (such as collagenase, plasmin, etc.) to overcome clumps and improve the quality of interface tissue material.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2015/026279 | 4/17/2015 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 61982531 | Apr 2014 | US |
